Form 4: Rhythm Pharmaceuticals Executive Sells Shares
Insider Transaction (Form 4)
Jennifer Kayden Lee, EVP, Head of North America of Rhythm Pharmaceuticals, Inc., sold 75,834 shares of common stock on August 13, 2026 for $117.38 per share.
Summary
- Option exercise/conversion: acquired 35,000 Common Stock at $24.29 ($850,150) on August 13, 2026; holds 54,233 after (Direct).
- Option exercise/conversion: acquired 21,601 Common Stock at $6.80 ($146,887) on August 13, 2026; holds 75,834 after (Direct).
- Open-market sale: disposed of 75,834 Common Stock at $117.38 ($8,901,531) on August 13, 2026 (Direct).
- Option exercise/conversion: disposed of 35,000 Stock Options (Right to Buy) on August 13, 2026; holds 36,283 after (Direct).
- Option exercise/conversion: disposed of 21,601 Stock Options (Right to Buy) on August 13, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $8,901,531 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Jennifer Kayden Lee — Officer (EVP, Head of North America)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-13 | Option exercise/conversion | Common Stock | 35,000 | $24 | $850.1K | 54,233 |
| 2026-08-13 | Option exercise/conversion | Common Stock | 21,601 | $7 | $146.9K | 75,834 |
| 2026-08-13 | Open-market sale | Common Stock | 75,834 | $117 | $8.9M | 0 |
| 2026-08-13 | Option exercise/conversion | Stock Options (Right to Buy) | 35,000 | — | — | 36,283 |
| 2026-08-13 | Option exercise/conversion | Stock Options (Right to Buy) | 21,601 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-13 | Option exercise/conversion (35,000 shares) |
| 2026-08-13 | Option exercise/conversion (21,601 shares) |
| 2026-08-13 | Open-market sale (75,834 shares) |
| 2026-08-13 | Option exercise/conversion (35,000 shares) |
| 2026-08-13 | Option exercise/conversion (21,601 shares) |
Keywords
insider transaction, Form 4, RYTM, RHYTHM PHARMACEUTICALS, INC., bearish, Jennifer Kayden Lee
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.